We Develop Drug Treatments Using Physics Based Modeling and Artificial Intelligence

Kevin Short, PhD

Head of Chemistry

Kevin joined Verseon because his life goal is to see the largest possible number of new chemical entities with novel modes of action become life-changing drugs. He is instrumental in guiding Verseon’s medicinal chemistry campaigns and IP strategy for protecting Verseon’s novel drug candidates. Kevin has also run medicinal chemistry programs at Johnson & Johnson and Ontogen. He is an inventor on 8 patents. Kevin received his BS from Imperial College and his PhD in Chemistry from the University of Exeter.